Recently, Narazaki et al. [53] showed in a model in which transferred T cells are used to prevent tumor recurrence in a rechallenge model, that for agonistic anti-4-1BB therapy, 4-1BB was more important on the transferred T cells with lesser effects on host cells. The gene discussed is TNFRSF9; the disease is neoplasm.